ClinicalTrials.govpublic full text
Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
cholangiocarcinoma, inoperable, kras mutation, biological treatment, combination chemotherapy, monoclonal antibody, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 833525
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.